Academic Journal
#2549 Real world data of dapagliflozin effect on proteinuria in primary glomerulopathies in Croatia
| العنوان: | #2549 Real world data of dapagliflozin effect on proteinuria in primary glomerulopathies in Croatia |
|---|---|
| المؤلفون: | Brinar, Ivana Vukovic, Laganovic, Mario, Zagorec, Nikola, Šimunov, Bojana, Radić, Josipa, Gulin, Tonko, Altabas, Karmela, Bubic, Ivan, Šimundić, Tihana, Ivandic, Ema, Pranjić, Ita Jelić, Horvatic, Ivica |
| المصدر: | Nephrology Dialysis Transplantation ; volume 39, issue Supplement_1 ; ISSN 0931-0509 1460-2385 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| الوصف: | Background and Aims SGLT2 inhibitors, namely dapagliflozin, proved to slow progression of kidney disease in randomized clinical trials. Our aim was to assess real world efficacy of dapagliflozin on proteinuria level in primary glomerulopathies (GN). Method adult patients with biopsy proven glomerulonephritis from all university hospitals in Croatia who started dapagliflozin as a standard of care were enrolled. Data were analyzed if patients had at least six months of follow up. None of the patients were on immunosuppression. Data are shown as N (%) or median with interquartile range (IQR) and accompanied p levels. Results Overall 118 patients, predominantly male 84 (71.8%) of average age of 52 years (min–max 20–76), were enrolled. Most of the patients had IgA nephropathy (IgAN) (N = 55;46.6%), followed by membranous nephropathy (N = 27;22.9%), FSGS (N = 19;16.1%), membranoproliferative GN (N = 8;6.8%), Alport syndrome (N = 8;6.8%). 95.8% of patients were on ACE inhibitors or angiotensin receptor blockers and 10.7% were on mineralocorticoid receptor inhibitors and RAAS blockage was not significantly upscaled during follow up. During the median follow up of 12.2 (7.5-18.6) months, proteinuria was significantly reduced from 1139 (534–2265) to 701 (305-1543) mg/dU; p < 0.001. When divided by glomerulonephritis type, statistically significant reduction of proteinuria was observed in patients with IgAN and Alport syndrome, while trend of reduction of proteinuria was observed in all types of GN. There was a slight reduction in eGFR levels (54 (43-78) vs. 52 (39–73) ml/min/1,73 m²; p < 0.001) and rise in creatinine values (122 (89–149) vs. 128 (91–159) μmol/l; p < 0.001). There was a significant reduction in systolic (130 (120-140) vs.125 (115-134) mmHg; p < 0.001) and diastolic blood pressure (80 (75-90) vs. 80 (70-85) mmHg; p < 0.001). Reduction of uric acid level was noticed (377 (313–460) vs.343 (294–422); p < 0.001), while there was no effect on LDL levels (2.6 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ndt/gfae069.320 |
| الاتاحة: | http://dx.doi.org/10.1093/ndt/gfae069.320 https://academic.oup.com/ndt/article-pdf/39/Supplement_1/gfae069-0320-2549/57791809/gfae069-0320-2549.pdf |
| Rights: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| رقم الانضمام: | edsbas.D35661D8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ndt/gfae069.320 |
|---|